Drug Giants Blink — Prices Get Pegged

Nine more drug companies agreed to tie U.S. prices to those in wealthy nations, strengthening President Trump’s drive to cut prescription costs.

Story Snapshot

The White House says 26 drugmakers now back the most-favored-nation pricing plan.
New signers include Alcon, Astellas, Teva, Sun Pharma, and others named in reports.
Coverage spans drugs for cancer, glaucoma, Parkinson’s disease, and more.
The administration projects more than $600 billion in savings over 10 years.

What Changed: Nine More Companies Sign On

On August 31, the White House announced that nine additional pharmaceutical companies joined the administration’s most-favored-nation pricing effort. Reports identified the new participants as Alcon, Astellas Pharma, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB, adding to earlier agreements with major firms reached this year. The administration said the total count now stands at 26 companies that have agreed to align prices with those paid in comparable developed nations.

The White House framed the new round as building on deals secured before August. Earlier in the year, officials said they had 17 large manufacturers on board. The August 31 expansion brings the total to 26, which administration materials and coverage describe as representing roughly nine-tenths of the branded market by share. Reuters previously reported companies had outlined terms such as tariff relief and a federal direct-to-consumer channel, signaling a policy structure set before this expansion.

How The Policy Works And What It Covers

White House releases describe the policy’s core rule: bring U.S. prices “in line with the lowest paid by comparable developed nations.” That simple anchor is easy to explain but complex to execute in practice across drugs and payers. The latest batch of agreements, according to reports, touches treatments for hemophilia, Parkinson’s disease, glaucoma, liver disease, several cancers, transplants, and infectious diseases, suggesting broader clinical reach than a narrow pilot. The administration says participation aims to help patients across insurance types.

The White House has also highlighted examples and adjacent deals to show traction. An association brief summarized pricing for popular metabolic drugs at about $245 per month for Medicare under a related action, offering a concrete reference for a high-demand class. While those specific price points are not the whole program, they illustrate how international reference anchors can filter into real budgets. The government argues that tying prices to peer nations pressures list and net prices toward a lower band over time.

Why It Matters For Families And Politics

President Trump is making prescription affordability a centerpiece of his second-term agenda. The White House says the combined effort could save more than $600 billion over the next decade, a headline number used to signal scale even as technical scoring details are not public in these materials. For many Americans, drug costs feel like a rigged game that favors large companies and well-connected middlemen. A visible price cap tied to rich-country peers addresses that broad frustration directly.

President Donald Trump announced an expansion of his Most Favored Nation drug pricing initiative on Monday afternoon from the White House.

READ MORE: https://t.co/P1V4rWAAa5 pic.twitter.com/rH0f2o6m4S

— ABC News 4 (@ABCNews4) August 31, 2026

The agreements arrive in a climate where both right and left believe Washington often serves insiders first. Conservatives see high prices as the result of global deals and complex rebates. Liberals see a system that widens gaps between the haves and the have-nots. Pegging prices to what other wealthy countries pay is a rare, plain rule most people can understand. Reports say earlier company lists showed deal terms of about three years for some firms, which will require continued management to sustain results beyond initial periods.